SUSCEPTIBILIDADE A ANTIFUNGICOS E PRODUÇAO DE ENZIMAS POR LEVEDURAS DO <I>(LEVADURAS DEL)</I> GENERO CANDIDA ISOLADAS <I>(AISLADAS)</I> DE PACIENTES COM HIV/AIDS





SUSCEPTIBILIDADE A ANTIFUNGICOS E PRODUÇAO DE ENZIMAS POR LEVEDURAS DO (LEVADURAS DEL) GENERO CANDIDA ISOLADAS (AISLADAS) DE PACIENTES COM HIV/AIDS

(especial para SIIC © Derechos reservados)
A candidíase é a (constituye la) infecção fúngica mais frequente entre os pacientes portadores do vírus da imunodeficiência humana.
pupulin9.jpg Autor:
Aurea Regina Pupulin
Columnista Experta de SIIC

Institución:
Universidade Estadual de Maringá (UEM)


Artículos publicados por Aurea Regina Pupulin
Coautores
Paula Galdino Carvalho* Celso Vataru Nakamura** 
Mestre, Universidade Estadual de Maringá (UEM), Maringá, Brasil*
PhD, Universidade Estadual de Maringá (UEM), Maringá, Brasil**
Recepción del artículo
27 de Septiembre, 2011
Aprobación
5 de Octubre, 2012
Primera edición
18 de Octubre, 2012
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
A candidíase é a (constituye la) infecção fúngica mais frequente entre os pacientes portadores do vírus da imunodeficiência humana. Este estudo objetivou o isolamento (el aislamiento), identificação, avaliação do (evaluación del) perfil de susceptibilidade e fatores de virulência de leveduras do gênero Candida provenientes de pacientes HIV/AIDS. As amostras foram coletadas (Las muestras se recolectaron) de 100 pacientes em diferentes sítios anatômicos (boca, trato gastrointestinal e vaginal), cultivadas em meio (en medio) ágar Sabouraud, e identificadas através da cultura em meio (a través de cultivo en medio) diferencial CHROMágar Candida e pela técnica da reação em cadeia da (y por la técnica de reacción en cadena de la) polimerase (PCR). O teste de (La prueba de) susceptibilidade in vitro aos (a los) antifúngicos fluconazol, anfotericia B e nistatina foram determinados através da técnica de microdiluição em caldo (en caldo). A infectividade foi avaliada através da (se validó por medio de la) produção de fosfolipases e hemolisinas. Do total (De un total) de 45 leveduras isoladas, houve maior (hubo mayor) prevalência de C. albicans, seguida por C. glabrata, C.parapisilosis, C.tropicalis e C. krusei. Foram submetidas ao (Se sometieron a la) teste de suscptibilidade 43 (95%) das amostras, onde a (en la que la) concentração inibitória mínima foi determinada. Todos os isolados foram sensíveis a (Todos los aislamientos eran sensibles a) anfotericina B e a nistatina, enquanto 60.6% foram sensíveis ao fluconazol, 6.9% sensíveis dose-dependente e 32.5% apresentaram resistência ao (presentaron resistencia al) fluconazol. As espécies C. glabrata e C. tropicalis apresentaram CIMs maior para o fluconazol do que os encontrados para C. albicans. Apresentou produção de fosfolipase 62% das amostras e atividade hemolítica 87%.

Palabras clave
Candida sp, HIV/AIDS, antifúngicos


Artículo completo

(castellano)
Extensión:  +/-6.4 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Thrush or Candida albicans is one of the most common fungal infections among patients with human immunodeficiency virus. The isolation, identification and evaluation of susceptibility and virulence factors of Candida yeasts from HIV/AIDS patients are provided. Samples, collected from different anatomical sites (mouth, gastrointestinal tract and vagina) of 100 patients, were grown in Sabouraud agar and identified by culture in differential medium CHROMagar Candida and by polymerase chain reaction (PCR) technique. The in vitro susceptibility test for antifungal fluconazole, amphotericin B and nystatin were determined by broth micro-dilution technique. Infectivity was assessed through the production of phospholipases and hemolysins. Candida albicans was the most prevalent among the 45 isolated yeasts, followed by C. glabrata, C. parapisilosis, C. tropicalis and C. krusei. Forty-three (95%) samples were tested for susceptibility in which minimum inhibitory concentration was determined. All isolates were susceptible to amphotericin B and nystatin, whereas 60.6% were susceptible to fluconazole; 6.9% were susceptible-dose dependent and 32.5% were resistant to fluconazole. The species C. glabrata and C. tropicalis showed higher CIMs for fluconazole than those found for C. albicans. Furthermore, 62% of samples produced phospholipase and 87% produced hemolytic activity.

Key words
Candida sp, HIV/AIDS, antifungal


Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Diagnóstico por Laboratorio, Infectología
Relacionadas: Bioquímica, Epidemiología, Medicina Interna



Comprar este artículo
Extensión: 6.4 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Aurea Regina Pupulin, Universidade Estadual de Maringá (UEM), Av Colombo 5790 bloco I-90 DBS/parasitologia, Maringá, Brasil
Bibliografía del artículo
1. UNAIDS REPORT ON THE GLOBAL AIDS EPIDEMIC; 2010 Disponível em http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf
2. Ministério da Saúde. Boletim Epidemiológico AIDS-DST. Brasília, DF: Ministério da Saúde; 2010. Disponível em http://www.aids.gov.br
3. Tapia C, Gonzales P, Pereira A, Pérez J, Noriega LM, Palavecino ES. Susceptibilidad antifúngica de Candida albicans recuperadas de pacientes com SIDA y candidiasis orofaríngea y esofágica. Revista Médica de Chile 131:515-519, 2003.
4. WHO. Investing in a Comprehensive Health Sector Response to AIDS/HIV. Jan. 2004-Dec. 2005. http://www.who.int /3by5/en/HIV_AIDSplan.pdf
5. Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrobial Agents and Chemotherapy 41:535-539, 1997.
6. Samaranayake LP. Oral mycoses in human immunodeficiency vírus infection: a review. Oral surgery, Oral Medicine, Oral Pathology 73:171-180, 1992.
7. Reedding SWMA, Pfaller SA, Messer JA, Smith J, Prows LL, Bradley AW, Fothergill MG. Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection. Journal of Clinical Microbiology 35:1761-1765, 1997.
8. Achkar JM, Fries BC. Candida Infections of the Genitourinary Tract. Clinical Microbiology Reviews 23:253-273, 2010.
9. Same-Ekobo A, Lohoue J, Mbassi A. A clinical and biological study of parasitic and fungal diarrhea in immunossuppressed patients in urban suburban area of Yaounde. Sante 7:49-354, 1997.
10. Pfaller MA, Diekema D.J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clinical Microbiology and Infection 10:11-23, 2004.
11. Sanchez-Vargas lO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gaitán-Cepeda lA, Quindós G. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Revista Iberoamericana de Micologia 22:83-92, 2005.
12. McGinnis MR, RinaldiI MG. Antifungical Drugs: Mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids. In: Victor Lorian MD. Antibiotics in laboratory medicine. Washington D.C.: Willians & Wilkins; 1996.
13. Schechter M. Rachid M. Manual de HIV/AIDS. Revinter, Rio de Janeiro; 2004.
14. Vazquez JA. Management of oropharyngeal and esophageal candidiasis in patients with HIV infection. Journal of HIV Therapy 4:1-19, 2010.
15. Singleton DR, Hazen KC. Differential surface localization and temperature-dependent expression of the Candida albicans CSH1 protein. Microbiology 150:285-292, 2004.
16. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. TRENDS in Microbiology 9:327-335, 2001.
17. Ivanoska N. Phospholipases as a factor of pathogenicity in microorganisms. Journal of Molecular Catalysis B: Enzymatic 22:357-61, 2003.
18. Weinberg ED. Iron and infection. Microbiological Reviews 42:45-66, 1978.
19. Manns JM, Mosser DM, Buckley HR. Production of a hemolytic factor by Candida albicans. Infection and Immunity 62:5154-5156, 1994.
20. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual Of Clinical Microbiology. 6a ed., Washington DC: ASM Press; 1995.
21. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activity of Voriconazole and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrobial Agentes and Chemoterapy 42:161-163, 1998.
22. Houang ET, Chu KC, Koehler AP, Cheng AF. Use of CHROMagar Candida for genital specimens in the diagnostic laboratory. Journal of Clinical Pathology 50:563-565, 1997.
23. CLSI. Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M27-A. Clinical and Laboratory Standards Institute. Wayne, Pennsylvania, EE.UU.; 2005.
24. Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gaitán-Cepeda LA, Quindós G. Oral Candida isolates colonizing or infecting human immunodeficiency virus infected and healthy persons in Mexico J Clin Microbiol 43(8):4159-62, 2005.
25. Favalessa OC, Martins Mdos A, Hahn RC. Mycological aspects and susceptibility in vitro the yeast of the genus Candida from HIV-positive patients in the State of Mato Grosso..Rev Soc Bras Med Trop 43(6):673-7, 2010.
26. Vandeputte P, Larcher G, Bergès T, Renier G, Chabasse D, Bouchara JP. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis.Antimicrob Agents Chemother 49(11):4608-15, 2005.
27. Bizerra FC, Nakamura CV, de Poersch C, Estivalet Svidzinski TI, Borsato Quesada RM, Goldenberg S, Krieger MA, Yamada-Ogatta SF. Characteristics of biofilm formation by Candida tropicalis and antifungal resistance.FEMS Yeast Res 8(3):442-50, 2008.
28. Negri M, Martins M, Henriques M, Svidzinski TI, Azeredo J, Oliveira R. Examination of potential virulence factors of Candida tropicalis clinical isolates from hospitalized patients. Mycopathologia 169(3):175-82, 2010.
29. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42(10):4419-31, 2004.
30. Fidel PL Jr, Vazquez JA, Sobel JD Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12(1):80-96, 1999.
31. Nucci M, Colombo AL. Emergence of resistant Candida in neutropenic patients. Braz J Infect Dis 2002 Jun;6(3):124-8. Epub 2003. Review.
32. Hachem R, Sipsas NV, Lewis RE, Tarrand J, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115(20):4745-52, 2009.
33. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 50(7):2522-4, 2006.
34. Luo G, Samaranayake LP, Yau JY. Candida species exhibit differential in vitro hemolytic activities.J Clin Microbiol 39(8):2971-4, 2001.
35. França EJ, Fávero D, Scremin H, Oliveira MT, Furlaneto-Maia L, Quesada RM, Furlaneto MC. Hemolysis produced by Candida tropicalis isolates from clinical samples Rev Soc Bras Med Trop 43(3):318-21, 2010.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618